An investigation on interleukin 18 expression in cardiovascular diseases by Dashti, Ameneh & Firouzabadi, Negar
 
Pharmacy Updates 2018 
 
 










 School of Pharmacy, Shiraz 
University of Medical Sciences, 
Shiraz, Iran.  
b
 Department of Pharmacology & 
Toxicology, School of Pharmacy, 
Shiraz University of Medical 
Sciences, Shiraz, Iran. 
 
Abstract Presenter: 
Ameneh Dashti; Pharmacy intern; 
School of Pharmacy, Shiraz 
University of Medical Sciences, 
Shiraz, Iran 
E-mail: adashti@sums.ac.ir  
 
*Correspondance: 
Negar Firouzabadi; Ph.D.;  Assistant 
Professor, Department of 
Pharmacology & Toxicology, School 
of Pharmacy, Shiraz University of 





Introduction: Interleukin 18 is a proinflammatory cytokine from IL-1 cytokine 
family and plays a central role in inflammation. In fact, it is an IFN-gamma-inducing 
factor (IGIF). Interleukin 18 increases the response of Th1 cells, cells that are 
dominant in atherogenesis and cause growth of atherosclerosis plaques. The 
concentration of circulating IL-18 predicts the probable mortality from 
cardiovascular problems in CAD patients and plays a key role in atherosclerosis, 
which is one of the reasons for CHF.  
 
Methods and Results: The proinflammatory cytokines of IL-1β, TNF-α, IL-6 and 
LPS induce IL-18 gene expression and IL-18 causes an increase in the 
proinflammatory cytokines of IL-1β, IL-6, TNF-α, GM-CSF growth factor, and 
nitric oxide and cyclooxygenase (cox-2) and thus interleukin 18 causes 
inflammatory diseases. The Heterodimeric IL-18 receptor is expressed in a variety of 
cells, including macrophages, T lymphocytes, and NK cells. These cells have a key 
role in atherosclerotic plaque rupture. The IL-18 binding protein, a natural 
endogenous inhibitor that is present in high concentration in the extracellular 
environment and is highly associated with IL-18, interferes with its receptor 
interaction, thus inhibits IL-18 activity. The level of IL-18 in coronary patients 
significantly increases and its serum level in CAD patients who die from 
cardiovascular problems is more than CAD patients who are still alive. In animal 
models, IL-18 administration has been shown to increase the size and number of 
clots associated with T lymphocytes and this effect has been eliminated in animals 
with interferon-gamma deficiency. Angiotensin II increases the expression of IL-18 
in arterial smooth muscle cells by AT1 receptors. Losartan will slow down this 
process. We also know that losartan increases EF and decreases TNF-α and 
improves left ventricular function in HF patients. It has been shown in a study that 
stimulation of β-adrenergic receptors by isoproterenol during a series of events 
increases the transcription and expression of the IL-18 gene, and these events can 
occur similarly in HF. 
 
Conclusions: There is a strong association between serum IL-18 level and future 
cardiovascular problems so Inhibition of IL-18 signaling by IL-18 binding protein 
will be a new therapeutic strategy. 
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